Comments
Loading...

Viracta Therapeutics Analyst Ratings

VIRXOTCPK
Logo brought to you by Benzinga Data
$0.0170
At close: May 16, 1:49 PM EDT
$0.0168
-0.00020-1.18%
Pre-Market: Apr 14, 8:00 AM EDT
Consensus Rating1
Outperform
Highest Price Target1
$11.00
Lowest Price Target1
$0.25
Consensus Price Target1
$5.04

Viracta Therapeutics Analyst Ratings and Price Targets | OTC:VIRX | Benzinga

Viracta Therapeutics Inc has a consensus price target of $5.04 based on the ratings of 7 analysts. The high is $11 issued by Oppenheimer on May 23, 2024. The low is $0.25 issued by Rodman & Renshaw on December 27, 2024. The 3 most-recent analyst ratings were released by Rodman & Renshaw, RBC Capital, and Leerink Partners on December 27, 2024, November 14, 2024, and August 16, 2024, respectively. With an average price target of $1.75 between Rodman & Renshaw, RBC Capital, and Leerink Partners, there's an implied 10194.12% upside for Viracta Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Rodman & Renshaw
RBC Capital
Leerink Partners
Oppenheimer
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Viracta Therapeutics

Buy NowGet Alert
12/27/2024Buy Now1370.59%Rodman & Renshaw$3.5 → $0.25DowngradeBuy → NeutralGet Alert
11/14/2024Buy Now11664.71%RBC Capital
Gregory Renza47%
$4 → $2MaintainsOutperformGet Alert
08/16/2024Buy Now17547.06%Leerink Partners
Andrew Berens48%
$5 → $3DowngradeOutperform → Market PerformGet Alert
08/15/2024Buy Now23429.41%RBC Capital
Gregory Renza47%
$6 → $4MaintainsOutperformGet Alert
05/23/2024Buy Now64605.88%Oppenheimer
Hartaj Singh45%
$13 → $11MaintainsOutperformGet Alert
04/17/2024Buy Now76370.59%Oppenheimer
Hartaj Singh45%
→ $13MaintainsOutperformGet Alert
04/16/2024Buy Now23429.41%HC Wainwright & Co.
Robert Burns42%
$4 → $4ReiteratesBuy → BuyGet Alert
03/12/2024Buy Now23429.41%HC Wainwright & Co.
Robert Burns42%
$4 → $4ReiteratesBuy → BuyGet Alert
01/05/2024Buy Now23429.41%HC Wainwright & Co.
Robert Burns42%
$10 → $4MaintainsBuyGet Alert
11/10/2023Buy Now35194.12%RBC Capital
Gregory Renza47%
$7 → $6MaintainsOutperformGet Alert
10/05/2023Buy Now41076.47%RBC Capital
Gregory Renza47%
→ $7ReiteratesOutperform → OutperformGet Alert
08/15/2023Buy Now41076.47%RBC Capital
Gregory Renza47%
→ $7ReiteratesOutperform → OutperformGet Alert
08/15/2023Buy Now29311.76%SVB Securities
Andrew Berens48%
$10 → $5MaintainsOutperformGet Alert
08/15/2023Buy Now58723.53%HC Wainwright & Co.
Robert Burns42%
$10 → $10ReiteratesBuy → BuyGet Alert
07/31/2023Buy Now58723.53%EF Hutton
Tony Butler42%
→ $10Initiates → BuyGet Alert
07/05/2023Buy Now58723.53%HC Wainwright & Co.
Robert Burns42%
$33 → $10ReiteratesBuy → BuyGet Alert
05/10/2023Buy Now194017.65%HC Wainwright & Co.
Robert Burns42%
$35 → $33MaintainsBuyGet Alert
05/09/2023Buy Now41076.47%RBC Capital
Gregory Renza47%
$8 → $7MaintainsOutperformGet Alert
05/08/2023Buy Now64605.88%SVB Securities
Andrew Berens48%
$11 → $11MaintainsOutperformGet Alert
03/27/2023Buy Now94017.65%Oppenheimer
Hartaj Singh45%
$14 → $16MaintainsOutperformGet Alert
03/14/2023Buy Now46958.82%RBC Capital
Gregory Renza47%
→ $8Reiterates → OutperformGet Alert
03/14/2023Buy Now205782.35%HC Wainwright & Co.
Robert Burns42%
→ $35Reiterates → BuyGet Alert
11/11/2022Buy Now46958.82%RBC Capital
Gregory Renza47%
$10 → $8MaintainsOutperformGet Alert
11/10/2022Buy Now64605.88%SVB Securities
Andrew Berens48%
→ $11MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Viracta Therapeutics (VIRX) stock?

A

The latest price target for Viracta Therapeutics (OTCPK:VIRX) was reported by Rodman & Renshaw on December 27, 2024. The analyst firm set a price target for $0.25 expecting VIRX to rise to within 12 months (a possible 1370.59% upside). 5 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Viracta Therapeutics (VIRX)?

A

The latest analyst rating for Viracta Therapeutics (OTCPK:VIRX) was provided by Rodman & Renshaw, and Viracta Therapeutics downgraded their neutral rating.

Q

When was the last upgrade for Viracta Therapeutics (VIRX)?

A

There is no last upgrade for Viracta Therapeutics

Q

When was the last downgrade for Viracta Therapeutics (VIRX)?

A

The last downgrade for Viracta Therapeutics Inc happened on December 27, 2024 when Rodman & Renshaw changed their price target from $3.5 to $0.25 for Viracta Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Viracta Therapeutics (VIRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on December 27, 2024 so you should expect the next rating to be made available sometime around December 27, 2025.

Q

Is the Analyst Rating Viracta Therapeutics (VIRX) correct?

A

While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a downgraded with a price target of $3.50 to $0.25. The current price Viracta Therapeutics (VIRX) is trading at is $0.02, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.